Clostridioides Difficile Infection Clinical Trial
Official title:
Phase III,Randomized,Double-blinded Clinical Trial to Evaluate the Effectiveness and Safety of Oral Vancomycin Vs Placebo in the Prevention of Recurrence of C.Difficile Infection in Patients Under Treatment With Systemic Antibiotic Therapy
A phase III randomized clinical trial in proportion 2:1 in favor of oral vancomycin (experimental treatment), multicentric, national, double-blinded, controlled with placebo. The main objective is to evaluate the effectiveness of treatment with oral vancomycin to reduce the incidence of Clostridioides difficile infection (CDI) in patients who suffered previous CDI and who need further hospitalization and treatment with systemic antibiotic therapy in the 90 days after the first CDI.
As secondary objectives the investigators intend to: - Evaluate the effectiveness of the treatment with oral vancomycin as part of the prophylaxis arsenal to prevent ICD in patients with previous ICD episodes stratified by the number of previous recurrences. - Compare the severity of recurrences in both study groups. - Compare the effectiveness of the treatment with oral vancomycin depending on the type of systemic antibiotic therapy prescribed. - Evaluate the tolerance and the safety of the treatment with oral vancomycin in terms of secondary effects and difficulty in therapeutic compliance. - Evaluate if the treatment with oral vancomycin has an effect in diminishing the severity of ICD recurrences. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03895593 -
Rescue Fecal Microbiota Transplantation for National Refractory Intestinal Infections
|
||
| Withdrawn |
NCT04679324 -
The Role of Mucosal Microbiome in the Development, Clearance and Recurrence of Clostridioides Difficile Infection
|
||
| Completed |
NCT04675723 -
The Role of Mucosal Microbiome in Recurrence of Clostridioides Difficile Infection
|
||
| Recruiting |
NCT05693077 -
Clostridioides Difficile Colonisation
|
Phase 1 | |
| Completed |
NCT04668014 -
The Characteristics and Role of Mucosal Microbiome After Treatment of Clostridioides Difficile Infection
|
||
| Completed |
NCT03183141 -
ECOSPOR IV: An Open-Label Study Evaluating SER-109 in Recurrent Clostridioides Difficile Infection
|
Phase 3 | |
| Recruiting |
NCT05709184 -
Lyophilized Fecal Microbiome Transfer vs. Vancomycin Monotherapy for Primary Clostridioides Difficile Infection
|
N/A | |
| Terminated |
NCT05526807 -
Ursodeoxycholic Acid in C. Difficile Infection
|
N/A | |
| Recruiting |
NCT06306014 -
Evaluation of EXL01, a New Live Biotherapeutic Product to Prevent Recurrence of Clostridioides Difficile Infection in High-risk Patients
|
Phase 1/Phase 2 | |
| Recruiting |
NCT06237452 -
VE303 for Prevention of Recurrent Clostridioides Difficile Infection
|
Phase 3 | |
| Terminated |
NCT04802837 -
Safety, Tolerability and the Pharmacokinetics of Ridinilazole in Adolescent Subjects
|
Phase 3 | |
| Active, not recruiting |
NCT04885946 -
Fecal Microbiota Transplantation for Early Clostridioides Difficile Infection
|
N/A | |
| Recruiting |
NCT04305769 -
Alanyl-glutamine Supplementation for C. Difficile Treatment (ACT)
|
Phase 2 | |
| Recruiting |
NCT06106698 -
Washed Microbiota Transplantation for Clostridioides Difficile Infection
|
||
| Active, not recruiting |
NCT04781387 -
Evaluation of CRS3123 vs. Oral Vancomycin in Adult Patients With Clostridioides Difficile Infection
|
Phase 2 | |
| Completed |
NCT03595553 -
Comparison of Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection
|
Phase 3 | |
| Completed |
NCT03595566 -
To Compare Ridinilazole Versus Vancomycin Treatment for Clostridium Difficile Infection
|
Phase 3 | |
| Completed |
NCT04725123 -
Addressing Personalized Needs in Clostridioides Difficile Infection
|
N/A | |
| Not yet recruiting |
NCT05852587 -
Xylitol Use for Decolonization of C. Difficile in Patients With IBD
|
Phase 1 | |
| Completed |
NCT03788434 -
Phase 2 Study of VE303 for Prevention of Recurrent Clostridioides Difficile Infection
|
Phase 2 |